CHICAGO — Including liquid biopsy in the initial diagnostic workup of patients with stage IV nonsquamous non-small cell lung cancer resulted in a quicker initiation of first-line therapy and a higher detection rate of actionable mutations.
These findings were presented at ASCO Annual Meeting, and patients undergoing liquid biopsy were compared with patients who received tissue-based molecular diagnostic testing.
“Tissue sequencing has been the gold standard, but we and others have demonstrated that layering in liquid biopsies in a concurrent fashion on tissue biopsies can improve